MedTrace Logo

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

NCT06073574 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-11-28

No results posted yet for this study

Summary

The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

Conditions

  • Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Interventions

DIAGNOSTIC_TEST

Cardiac MRI

MRI Scans as specified in the corresponding arm group.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Ionis Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2026-03-31
Completion
2026-04-30

Countries

  • United States
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06073574 on ClinicalTrials.gov